CA
NZ
UK
AU
IND
US
…
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
LENZ Therapeutics Inc is a Nasdaq-listed development-stage therapeutics company that appears to focus on discovering and developing novel treatments, but public disclosures are limited. Long-term growth may depend on clinical program progress, regulatory approvals, partnering or licensing deals and successful capital raises, which may make the company attractive to investors seeking exposure to early-stage biotech upside.
Key risks include early-stage clinical and regulatory uncertainty, high probability of trial failure, ongoing financing and dilution risk, limited operating history and sparse public information that increases transparency risk.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-09-30 | 2022-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-09-30 | 2022-12-31 |
| Income before tax | -81.62M | -49.77M | -70.15M | -124.65M | -10.46M |
| Net income | -82.13M | -49.77M | -69.97M | -124.65M | -10.81M |
| Selling general administrative | 91.14M | 28.81M | 12.93M | - | 4.36M |
| Gross profit | 18.38M | -0.06M | -2.41M | -2.41M | 15.00M |
| Reconciled depreciation | 0.29M | 0.06M | 0.01M | - | 0.01M |
| Ebit | -81.62M | -49.77M | -70.15M | -73.11M | -10.46M |
| Ebitda | -81.34M | -49.71M | -70.13M | -70.70M | -10.46M |
| Depreciation and amortization | 0.29M | 0.06M | 0.01M | 2.41M | 0.01M |
| Operating income | -91.14M | -58.61M | -72.43M | -73.11M | -10.48M |
| Other operating expenses | 110.23M | 58.61M | 72.43M | 73.11M | 25.48M |
| Tax provision | 0.50M | 0.00M | -0.18M | - | 0.35M |
| Interest income | 9.76M | 8.55M | 2.19M | - | - |
| Net interest income | 9.76M | 8.55M | 2.19M | - | - |
| Income tax expense | 0.50M | 0.00M | -0.18M | - | 0.35M |
| Total revenue | 19.09M | 0.00M | 0.00M | - | 15.00M |
| Total operating expenses | 109.52M | 58.55M | 72.43M | 70.70M | 25.48M |
| Cost of revenue | 0.70M | 0.06M | 2.41M | 2.41M | 8.35M |
| Total other income expense net | 9.51M | 8.84M | 2.28M | -51.54M | 0.02M |
| Net income from continuing ops | -82.13M | -49.77M | -69.97M | - | -10.81M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-09-30 | 2022-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-09-30 | 2022-12-31 |
| Total assets | 305.88M | 215.30M | 70.38M | 188.46M | 46.95M |
| Other current assets | 6.64M | 2.89M | 1.45M | 2.16M | 2.20M |
| Total liab | 21.54M | 11.22M | 163.09M | 4.87M | 71.12M |
| Total stockholder equity | 284.34M | 204.08M | -92.71M | 183.58M | -24.17M |
| Other current liab | 16.55M | 5.58M | 12.67M | 4.26M | 4.29M |
| Common stock | 0.00M | 0.00M | 0.01M | 0.00M | 0.01M |
| Capital stock | 0.00M | 0.00M | 0.01M | - | 5.91M |
| Retained earnings | -227.14M | -145.01M | -95.25M | -367.05M | -25.28M |
| Other assets | - | - | -2.70M | - | 0.00M |
| Cash | 25.18M | 20.16M | 35.14M | 185.86M | 44.44M |
| Total current liabilities | 21.19M | 10.41M | 18.51M | 4.80M | 9.50M |
| Net debt | -24.36M | -18.78M | -34.81M | -185.50M | -44.19M |
| Short term debt | 0.47M | 0.57M | 0.14M | 0.28M | 0.10M |
| Short long term debt total | 0.81M | 1.38M | 0.33M | 0.36M | 0.25M |
| Other stockholder equity | 511.24M | 348.90M | 2.52M | 550.63M | 1.10M |
| Total current assets | 301.41M | 211.92M | 67.24M | 188.02M | 46.64M |
| Short term investments | 267.17M | 188.87M | 30.65M | - | 220.50M |
| Net receivables | 2.43M | 0.00M | - | - | - |
| Inventory | 2.94M | 0.00M | - | - | - |
| Accounts payable | 4.17M | 4.26M | 5.71M | 0.25M | 4.75M |
| Accumulated other comprehensive income | 0.24M | 0.20M | 0.01M | - | -1.05M |
| Non currrent assets other | 2.54M | 1.40M | 2.76M | - | 0.03M |
| Non current assets total | 4.46M | 3.39M | 3.13M | 0.43M | 0.31M |
| Capital lease obligations | 0.81M | 1.38M | 0.33M | - | 0.25M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-09-30 | 2022-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-09-30 | 2022-12-31 |
| Investments | -74.84M | -154.48M | -29.62M | - | -0.04M |
| Total cashflows from investing activities | -75.67M | -154.48M | -29.62M | - | -241.86M |
| Total cash from financing activities | 149.75M | 199.00M | 80.70M | 0.19M | 0.60M |
| Net income | -82.13M | -49.77M | -69.97M | -124.65M | -101.05M |
| Change in cash | 4.91M | -14.87M | -9.30M | 138.13M | -329.25M |
| Begin period cash flow | 20.27M | 35.14M | 44.44M | 47.73M | 376.98M |
| End period cash flow | 25.18M | 20.27M | 35.14M | 185.86M | 47.73M |
| Total cash from operating activities | -69.17M | -59.39M | -60.38M | -90.01M | -87.98M |
| Issuance of capital stock | 147.75M | 79.51M | 82.98M | - | 30.13M |
| Depreciation | -3.12M | 0.06M | 0.01M | 2.41M | 8.35M |
| Other cashflows from investing activities | - | - | 1.90M | - | - |
| Change to inventory | -4.28M | 0.00M | - | - | - |
| Change to account receivables | -0.33M | 0.00M | - | - | - |
| Sale purchase of stock | - | - | -0.07M | -0.07M | -0.08M |
| Other cashflows from financing activities | - | 119.49M | 80.50M | 226.35M | 30.26M |
| Capital expenditures | 0.83M | 0.47M | 0.03M | 10.86M | 6.59M |
| Change in working capital | 3.25M | -13.09M | 9.41M | -39.22M | -7.21M |
| Stock based compensation | 12.55M | 6.37M | 1.34M | - | 0.72M |
| Other non cash items | 0.28M | -2.95M | -1.18M | 78.63M | 11.93M |
| Free cash flow | -70.00M | -59.86M | -60.41M | -100.86M | -94.57M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| LENZ LENZ Therapeutics Inc |
-0.44 12.61% |
3.05 | - | - | 6.19 | 0.64 | 2.65 | -7.99 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
201 Lomas Santa Fe Drive, Solana Beach, CA, United States, 92075
858 925 7000
152
| Name | Title | Year Born |
|---|---|---|
| Mr. Evert B. Schimmelpennink | President, CEO, Secretary & Director | 1972 |
| Mr. Shawn Olsson | Chief Commercial Officer | 1983 |
| Mr. Marc G. Odrich M.D. | Chief Medical Officer | 1959 |
| Mr. James W. McCollum | Co-Founder & Director | 1955 |
| Mr. Gerald Horn | Senior Scientific Advisor & Founder | NA |
| Mr. Daniel R. Chevallard CPA | Chief Financial Officer | 1980 |
| Mr. Domenick Porfidia | Vice President of Sales | NA |
| Mr. David Murphy | Senior Director of Marketing & Alliance Development | NA |
| Mr. David Choromanski | Vice President of Marketing | NA |
| Ms. Melissa Rosness | Senior Vice President of Manufacturing Operations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...